NASDAQ:HGEN

Humanigen (HGEN) Stock Forecast, Price & News

$0.0091

0.00 (-8.08%)

(As of 05:37 PM ET)

Compare

Today's Range: $0.0090
▼
$0.01
50-Day Range: $0.01
▼
$0.20
52-Week Range: $0.01
▼
$0.26

Volume: 681,124 shs
Average Volume: 2.94 million shs
Market Capitalization: $1.08 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $0.50

About Humanigen (NASDAQ:HGEN) Stock

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1, as well as treats a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.

HGEN Price History

30 days | 90 days | 365 days | Advanced Chart

HGEN Stock News Headlines

August 11, 2023 | uk.finance.yahoo.com

Humanigen, Inc. (HGEN) stock price, news, quote & history – Yahoo Finance

August 7, 2023 | finance.yahoo.com

Humanigen Announces First Participant Dosed in RATinG Trial of Lenzilumab for Early Treatment of Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation

September 27, 2023 | Chaikin Analytics (Ad)

"This Could be the Biggest Stock Story of 2023"

A.I. is set to create $7 trillion in new wealth but most investors are buying the wrong stocks. Learn what Wall Street insiders are buying here.

July 30, 2023 | proactiveinvestors.com

Humanigen stock removed from S&P Total Market Index as firm faces...

July 28, 2023 | proactiveinvestors.com

Humanigen stock removed from S&P Total Market Index as firm faces bankruptcy

July 25, 2023 | marketwatch.com

Humanigen Shares Plunge 73% as Business Combination Fails, Going Concern Issues Raised

July 25, 2023 | markets.businessinsider.com

Why Is Humanigen (HGEN) Stock Down 72% Today?

July 25, 2023 | msn.com

Humanigen (NASDAQ:HGEN) Nosedives with Bankruptcy Looming Large

September 27, 2023 | Stansberry Research (Ad)

A 73-Year-Old Market Signal With 95% Accuracy Just Flashed

This signal has flashed just 24 times in the past 73 years – and it has signaled the exact moment to move your money with 95% accuracy. Now, it's flashing again. Discover where here.

July 25, 2023 | seekingalpha.com

Humanigen to weigh bankruptcy as shares delist from Nasdaq

April 17, 2023 | nasdaq.com

Humanigen (HGEN) Surges on Lenzilumab Study Data for Leukemia

April 14, 2023 | finance.yahoo.com

Humanigen - Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel Mechanism of Action for Chronic Myelomonocytic Leukemia (CMML), an Orphan Form of Leukemia

December 20, 2022 | finance.yahoo.com

Humanigen, Inc. (HGEN) Stock Historical Prices & Data - Yahoo Finance

November 14, 2022 | finance.yahoo.com

Humanigen Reports Third Quarter 2022 Financial Results

November 10, 2022 | finance.yahoo.com

Humanigen Announces Participation and Presentation at Jefferies London Healthcare Conference

October 31, 2022 | finance.yahoo.com

Humanigen Announces Retention of SC&H Capital as Financial Advisor

October 19, 2022 | stockhouse.com

2022-10-19 | NDAQ:HGEN | Press Release | Humanigen Inc. - Stockhouse

October 19, 2022 | benzinga.com

This Addiction Drug Shows Some Potential Against Long COVID Symptoms - Humanigen (NASDAQ:HGEN), GSK (NYSE - Benzinga

October 19, 2022 | benzinga.com

CLASS ACTION UPDATE for HGEN, SQ and OPEN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Be - Benzinga

October 18, 2022 | businesswire.com

GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Humanigen, Inc. Investors to Secure Counsel Before Important October 25 Deadline in Securities Class Action – HGEN - Business Wire

October 18, 2022 | prnewswire.com

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Humanigen, Inc. Investors to Secure Counsel Before Important October 25 Deadline in Securities Class Action - HGEN

October 17, 2022 | gurufocus.com

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Coupang, Humanigen, Latch, and Azure and Encourages Investors to Contact the Firm - GuruFocus.com

October 16, 2022 | benzinga.com

HGEN LAWSUIT ALERT: Levi & Korsinsky Notifies Humanigen, Inc. Investors of a Class Action Lawsuit and Upc - Benzinga

October 15, 2022 | stockhouse.com

2022-10-15 | NDAQ:HGEN | Press Release | Humanigen Inc. - Stockhouse

October 14, 2022 | gurufocus.com

HGEN SHAREHOLDER ALERT: Jakubo - GuruFocus.com

October 14, 2022 | stockhouse.com

2022-10-14 | NDAQ:HGEN | Press Release | Humanigen Inc. - Stockhouse

October 13, 2022 | gurufocus.com

HGEN LAWSUIT ALERT: Levi & Kor - GuruFocus.com

See More Headlines

Receive HGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Humanigen and its competitors with MarketBeat's FREE daily newsletter.

HGEN Company Calendar

Last Earnings: 11/12/2021
Today: 9/27/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:HGEN
CUSIP: N/A
CIK: 1293310
Web: www.humanigen.com
Phone: 650-243-3100
Fax: N/A
Employees: 6
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $0.50
High Stock Price Forecast: $0.50
Low Stock Price Forecast: $0.50
Forecasted Upside/Downside: +5,002.0%
Consensus Rating: Reduce
Rating Score (0-4): 1.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.51)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-70,730,000.00
Net Margins: -3,156.80%
Pretax Margin: -3,156.80%
Return on Equity: N/A
Return on Assets: -233.88%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.09
Quick Ratio: 0.09

Sales & Book Value

Annual Sales: $2.51 million
Price / Sales: 0.46
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.45) per share
Price / Book: -0.02

Miscellaneous

Outstanding Shares: 119,080,000
Free Float: 93,240,000
Market Cap: $1.17 million
Optionable: Optionable
Beta: -0.98

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. Cameron Durrant M.D. (Age 63)
MBA, Chairman, CEO & Acting CFO
Comp: $640k

Dr. Dale Chappell M.B.A. (Age 53)
M.D., MBA, Chief Scientific Officer & Director
Comp: $410k

Mr. Edward P. Jordan M.B.A. (Age 55)
Chief Commercial Officer
Comp: $364.75k

Mr. Robert Atwill M.B.A.
Sr. VP and Head of Asia-Pacific Region & Bus. Devel.

Key Competitors

View All Competitors

HGEN Stock - Frequently Asked Questions

Should I buy or sell Humanigen stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Humanigen in the last year. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" HGEN shares.
View HGEN analyst ratings or view top-rated stocks.
What is Humanigen's stock price forecast for 2023?: 2 Wall Street research analysts have issued 1 year target prices for Humanigen's shares. Their HGEN share price forecasts range from $0.50 to $0.50. On average, they expect the company's stock price to reach $0.50 in the next twelve months. This suggests a possible upside of 5,002.0% from the stock's current price.
View analysts price targets for HGEN or view top-rated stocks among Wall Street analysts.
How have HGEN shares performed in 2023?: Humanigen's stock was trading at $0.12 at the start of the year. Since then, HGEN shares have decreased by 91.8% and is now trading at $0.0098.
View the best growth stocks for 2023 here.
How were Humanigen's earnings last quarter?: Humanigen, Inc. (NASDAQ:HGEN) posted its earnings results on Friday, November, 12th. The company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($0.98) by $0.14. The business had revenue of $1.04 million for the quarter, compared to the consensus estimate of $0.40 million.

When did Humanigen's stock split?: Humanigen's stock reverse split on the morning of Monday, September 14th 2020. The 1-5 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 11th 2020. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.
What is Humanigen's stock symbol?: Humanigen trades on the NASDAQ under the ticker symbol "HGEN."
How do I buy shares of Humanigen?: Shares of HGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Humanigen's stock price today?: One share of HGEN stock can currently be purchased for approximately $0.01.
How much money does Humanigen make?: Humanigen (NASDAQ:HGEN) has a market capitalization of $1.17 million and generates $2.51 million in revenue each year. The company earns $-70,730,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis.
How can I contact Humanigen?: Humanigen's mailing address is 533 Airport Boulevard Ste. 400, Burlingame CA, 94010. The official website for the company is www.humanigen.com. The company can be reached via phone at 650-243-3100 or via email at ir@humanigen.com.

This page (NASDAQ:HGEN) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial